National Academy of Inventors names two Sanford-Burnham researchers as Charter Fellows

December 16, 2014

La Jolla, Calif., December 16, 2014 - Two professors at Sanford-Burnham Medical Research Institute (Sanford-Burnham) have been named Charter Fellows of the National Academy of Inventors (NAI): Erkki Ruoslahti, M.D., Ph.D., distinguished professor and former president of Sanford-Burnham, and Kristiina Vuori, M.D., Ph.D., current president of the Institute. Ruoslahti and Vuori are now part of a group of 414 NAI Fellows from more than 150 prestigious research universities, government, and nonprofit research institutions.

Election to the NAI Fellows is a significant professional distinction accorded to academic inventors who have demonstrated a highly prolific spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on quality of life, economic development, and the welfare of society.

"I'm honored to be named a Charter Fellow of the NAI," said Vuori. "I owe a large part of this distinction to the talented scientists, staff, and students I have worked with at Sanford-Burnham over the years."

Academic inventors are elected by their peers for innovative contributions in areas such as patenting and licensing, innovative discovery and technology, significant impact on society, and support and enhancement of innovation.

An internationally recognized leader in nanomedicine, Ruoslahti focuses his research on directing drugs to sites of disease. His main discovery and invention is the integrin-binding tripeptide motif RGD, a sequence within fibronectin that mediates cell attachment, and is found in numerous other cell-attachment proteins. His recent work has contributed to better tumor imaging and improving drug delivery to specific disease sites.

"It is a great honor to be named a Fellow of the NAI," said Ruoslahti. "There are so many giants of innovation that have received this distinction, and I'm grateful to be part of that group."

Ruoslahti holds 314 issued patents, and is the founder of the Center for Nanomedicine at UC Santa Barbara, a member of the U.S. National Academy of Sciences and the Institute for Medicine, and a member of the Academy of Arts and Sciences. He is the recipient of the Japan Prize, Gairdner Award, Clowes Award, Pasarow Award, and Jacobaeus Prize, and is a 2012 Thomson Reuters Citation Laureate. He is Knight and Commander of the Orders of the White Rose of Finland and the Lion of Finland.

Vuori joined the faculty of Sanford-Burnham in 1996 and has been president of Sanford-Burnham since 2010. She is also professor and holder of the Pauline and Stanley Presidential Chair, and served as director of Sanford-Burnham's NCI-designated Cancer Center from 2005 until 2013. Her main research focus is aimed at unraveling the molecular mechanisms of cancer metastasis, particularly the process that makes normal cells adhesion dependent. Normal cells adhere to their microenvironment for survival; if they become detached they will die. Cancer cells are somehow able to detach from their surroundings and move to other tissues in the body and survive and grow. Understanding the mechanisms of cell adhesion opens new approaches to preventing cancer metastasis.

Vuori was selected as a Pew Scholar in 1997 and she is an investigator of a Stand Up to Cancer Dream Team. She serves on the board of directors for the American Association for Cancer Research, California Institute for Regenerative Medicine, California Breast Cancer Research Program, and Florida Inventors Hall of Fame. She is the co-founder of three biotechnology companies.

The NAI Fellows will be inducted by the Deputy U.S. Commissioner for Patent Operations at the United States Patent and Trademark Office (USPTO) during the 4th Annual Conference of the National Academy of Inventors, on March 20, 2015, at the California Institute of Technology in Pasadena.

Included among all of the NAI Fellows are 61 presidents and senior leadership of research universities and nonprofit research institutes, 208 members of the other National Academies (NAS, NAE, IOM), 21 inductees of the National Inventors Hall of Fame, 16 recipients of the U.S. National Medal of Technology and Innovation, 10 recipients of the U.S. National Medal of Science, 21 Nobel Laureates, 11 Lemelson-MIT prize recipients, 107 AAAS Fellows, and 62 IEEE Fellows, among other awards and distinctions.

Sanford-Burnham Medical Research Institute is dedicated to discovering the fundamental molecular causes of disease and devising the innovative therapies of tomorrow. Sanford-Burnham takes a collaborative approach to medical research with major programs in cancer, neurodegeneration and stem cells, diabetes, and infectious, inflammatory, and childhood diseases. The Institute is recognized for its National Cancer Institute-designated Cancer Center, and expertise in drug discovery technologies. Sanford-Burnham is a nonprofit, independent institute that employs more than 1,100 scientists and staff in San Diego (La Jolla), Calif., and Orlando (Lake Nona), Fla. For more information, visit us at

Sanford-Burnham can also be found on Facebook at and on Twitter @sanfordburnham.


The National Academy of Inventors® is a 501(c)(3) non-profit member organization comprised of U.S. and international universities, and governmental and non-profit research institutions, with over 3,000 individual inventor members and Fellows spanning more than 200 institutions, and growing rapidly. It was founded in 2010 to recognize and encourage inventors with patents issued from the U.S. Patent and Trademark Office, enhance the visibility of academic technology and innovation, encourage the disclosure of intellectual property, educate and mentor innovative students, and translate the inventions of its members to benefit society. The NAI edits the multidisciplinary journal, Technology and Innovation, published by Cognizant Communication Corporation (NY). For more information, visit

Sanford-Burnham Prebys Medical Discovery Institute

Related Cancer Cells Articles from Brightsurf:

Cancer researchers train white blood cells to attacks tumor cells
Scientists at the National Center for Tumor Diseases Dresden (NCT/UCC) and Dresden University Medicine, together with an international team of researchers, were able to demonstrate that certain white blood cells, so-called neutrophil granulocytes, can potentially - after completing a special training program -- be utilized for the treatment of tumors.

New way to target some rapidly dividing cancer cells, leaving healthy cells unharmed
Scientists at Johns Hopkins Medicine and the University of Oxford say they have found a new way to kill some multiplying human breast cancer cells by selectively attacking the core of their cell division machinery.

Breast cancer cells use message-carrying vesicles to send oncogenic stimuli to normal cells
According to a Wistar study, breast cancer cells starved for oxygen send out messages that induce oncogenic changes in surrounding normal epithelial cells.

Breast cancer cells turn killer immune cells into allies
Researchers at Johns Hopkins University School of Medicine have discovered that breast cancer cells can alter the function of immune cells known as Natural killer (NK) cells so that instead of killing the cancer cells, they facilitate their spread to other parts of the body.

Breast cancer cells can reprogram immune cells to assist in metastasis
Johns Hopkins Kimmel Cancer Center investigators report they have uncovered a new mechanism by which invasive breast cancer cells evade the immune system to metastasize, or spread, to other areas of the body.

Engineered immune cells recognize, attack human and mouse solid-tumor cancer cells
CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia.

Drug that keeps surface receptors on cancer cells makes them more visible to immune cells
A drug that is already clinically available for the treatment of nausea and psychosis, called prochlorperazine (PCZ), inhibits the internalization of receptors on the surface of tumor cells, thereby increasing the ability of anticancer antibodies to bind to the receptors and mount more effective immune responses.

Engineered bone marrow cells slow growth of prostate and pancreatic cancer cells
In experiments with mice, researchers at the Johns Hopkins Kimmel Cancer Center say they have slowed the growth of transplanted human prostate and pancreatic cancer cells by introducing bone marrow cells with a specific gene deletion to induce a novel immune response.

First phase i clinical trial of CRISPR-edited cells for cancer shows cells safe and durable
Following the first US test of CRISPR gene editing in patients with advanced cancer, researchers report these patients experienced no negative side effects and that the engineered T cells persisted in their bodies -- for months.

Zika virus' key into brain cells ID'd, leveraged to block infection and kill cancer cells
Two different UC San Diego research teams identified the same molecule -- αvβ5 integrin -- as Zika virus' key to brain cell entry.

Read More: Cancer Cells News and Cancer Cells Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to